Candriam S.C.A. Has $25.91 Million Stake in Exelixis, Inc. $EXEL

Candriam S.C.A. grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 65.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 587,737 shares of the biotechnology company’s stock after buying an additional 232,597 shares during the period. Candriam S.C.A. owned approximately 0.22% of Exelixis worth $25,906,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in EXEL. Hemington Wealth Management increased its stake in Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 522 shares during the period. Byrne Asset Management LLC increased its position in shares of Exelixis by 129.0% during the second quarter. Byrne Asset Management LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 400 shares during the period. Family Legacy Financial Solutions LLC acquired a new position in shares of Exelixis in the second quarter valued at $33,000. Costello Asset Management INC bought a new position in Exelixis in the first quarter worth $39,000. Finally, Harbour Investments Inc. boosted its stake in Exelixis by 900.0% during the first quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company’s stock worth $41,000 after buying an additional 990 shares in the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on EXEL shares. Citigroup restated a “market outperform” rating on shares of Exelixis in a research note on Tuesday, October 21st. JMP Securities reissued a “market outperform” rating and issued a $50.00 price target on shares of Exelixis in a research report on Tuesday, July 29th. Stifel Nicolaus set a $43.00 price objective on Exelixis in a report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research note on Tuesday, October 21st. Finally, UBS Group raised their target price on Exelixis from $35.00 to $40.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.45.

Insider Activity

In related news, Director Stelios Papadopoulos sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $43.55, for a total value of $4,355,000.00. Following the completion of the sale, the director owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. This trade represents a 7.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mary C. Beckerle sold 24,622 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the transaction, the director owned 21,380 shares of the company’s stock, valued at $896,463.40. This trade represents a 53.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 173,005 shares of company stock valued at $7,443,678 over the last three months. 2.82% of the stock is owned by insiders.

Exelixis Stock Performance

Shares of EXEL stock opened at $42.35 on Friday. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62. The stock has a market capitalization of $11.35 billion, a PE ratio of 20.36, a PEG ratio of 0.79 and a beta of 0.32. The stock’s fifty day moving average is $39.40 and its 200-day moving average is $40.50.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.10. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The business had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. During the same quarter in the prior year, the company earned $0.47 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. As a group, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.